Swedish Orphan Biovitrum AB (SOBIs)

BATS Europe


	Symbol		Exchange		Currency
	SOBIV		Stockholm		SEK	Real-time
	SOBIs		BATS Europe		SEK	Delayed
	0MTD		London		SEK	Real-time

Currency in SEK

306.00

0.00(0.00%)

Closed04/12

Fair Value

Day's Range

306.00

306.00

52 wk Range

246.10

348.20

SOBIs Income Statement

Explore the detailed Swedish Orphan Biovitrum AB income statement, offering a comprehensive view of the company’s financial performance. Review essential metrics such as revenue, gross profit, operating income, and net income over selected periods. This page provides a clear breakdown of profitability and operational efficiency, helping you evaluate Swedish Orphan Biovitrum AB's growth trends and overall financial health.

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

14,248

15,261

15,529

18,790

22,123

Total Revenues Growth

+55.9%

+7.11%

+1.76%

+21%

+17.74%

Cost Of Revenues

3,319

3,225

3,484

4,413

4,952

Gross Profit

10,929

12,036

12,045

14,377

17,171

Gross Profit Growth

+62.54%

+10.13%

+0.07%

+19.36%

+19.43%

Gross Profit Margin %

76.71%

78.87%

77.56%

76.51%

77.62%

Other Operating Expenses, Total

6,232

7,573

8,251

9,857

12,507

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+73.35%	+21.52%	+8.95%	+19.46%	+26.88%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,448	1,594	1,987	2,252	2,743
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	4,807	5,981	6,294	7,637	9,773
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-23	-2	-30	-32	-9

Operating Income

4,697

4,463

3,794

4,520

4,664

Operating Income Growth

+50.11%

-4.98%

-14.99%

+19.14%

+3.19%

EBIT Margin %

32.97%

29.24%

24.43%

24.06%

21.08%

Net Interest Expenses

-236

-453

-419

-453

-1,084

Net Interest Expenses Growth

-345.28%

-91.95%

+7.51%

-8.11%

-139.29%

Interest Expense, Total

-241

-454

-419

-458

-1,111

Interest And Investment Income

5

1

-

5

27

Other Non Operating Expenses, Total

-58

-190

-17

-71

-140

EBT, Excl. Unusual Items

4,403

3,820

3,358

3,996

3,440

Gain (Loss) On Sale Of Assets

34

-2

-56

-

-1

Other Unusual Items, Total

-63

399

-7

-312

-450

EBT, Incl. Unusual Items

4,246

4,217

3,295

3,321

2,955

EBT, Incl. Unusual Items Growth

+37.77%

-0.68%

-21.86%

+0.79%

-11.02%

EBT, Incl. Unusual Items Margin

29.8%

27.63%

21.22%

17.67%

13.36%

Income Tax Expense

942

972

616

683

546

Net Income to Company

3,304

3,245

2,679

2,638

2,409

Minority Interest

-

-

-

-

-

Net Income

3,304

3,245

2,679

2,638

2,409

Net Income Growth

+36.64%

-1.79%

-17.44%

-1.53%

-8.68%

Net Income Margin %

23.19%

21.26%

17.25%

14.04%

10.89%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

3,304

3,245

2,679

2,638

2,409

Basic EPS - Continuing Operations

11.29

11.01

9.08

8.92

7.47

Basic EPS - Continuing Operations Growth

+25.84%

-2.46%

-17.55%

-1.71%

-16.34%

Diluted EPS - Continuing Operations

11.22

10.9

9.03

8.84

7.39

Diluted EPS - Continuing Operations Growth

+25.64%

-2.85%

-17.16%

-2.11%

-16.39%

Basic Weighted Average Shares Outstanding

292.65

294.66

295.05

295.6

322.66

Diluted Weighted Average Shares Outstanding

294.53

297.64

296.8

298.45

325.97

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

6,077

6,319

5,604

6,593

7,548

EBITDA Growth

+69.23%

+3.98%

-11.32%

+17.65%

+14.49%

EBITDA Margin %